(Q37794971)

23 August 2017

Alogliptin: a review of its use in the management of type 2 diabetes mellitus (English)

1 reference

23 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1

Lesley J Scott

1 reference

23 August 2017

1 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

70

1 reference

23 August 2017

15

1 reference

23 August 2017

2051-2072

1 reference

https://scigraph.springernature.com/pub.10.2165/11205080-000000000-00000

23 August 2017

0 references

cites work

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11205080-000000000-00000

Thiazolidinediones: do harms outweigh benefits?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11205080-000000000-00000

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11205080-000000000-00000

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

12 December 2020

Standards of medical care in diabetes--2009.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Thiazolidinediones and bone.

1 reference

12 December 2020

Effects of intensive glucose lowering in type 2 diabetes

1 reference

12 December 2020

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

1 reference

12 December 2020

The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice

1 reference

12 December 2020

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

1 reference

12 December 2020

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

12 December 2020

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

12 December 2020

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

1 reference

12 December 2020

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

12 December 2020

A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.

1 reference

12 December 2020

Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies

1 reference

12 December 2020

Diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

1 reference

12 December 2020

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

1 reference

12 December 2020

Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients

1 reference

12 December 2020

Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

12 December 2020

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

12 December 2020

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

1 reference

12 December 2020

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

1 reference

12 December 2020

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

1 reference

12 December 2020

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

1 reference

12 December 2020

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

1 reference

12 December 2020

Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice

1 reference

12 December 2020

10.2165/11205080-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20883057

Dimensions Publication ID

23 August 2017

0 references

1 reference

PubMed ID

20883057